{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:46:49Z","timestamp":1777045609186,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40266-016-0345-6","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T06:40:08Z","timestamp":1454654408000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial"],"prefix":"10.1007","volume":"33","author":[{"given":"Peter R.","family":"Sinnaeve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Danays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Van de Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"issue":"19","key":"345_CR1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1161\/CIRCULATIONAHA.107.182616","volume":"115","author":"KP Alexander","year":"2007","unstructured":"Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570\u201389.","journal-title":"Circulation"},{"issue":"8","key":"345_CR2","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.94.8.1826","volume":"94","author":"HD White","year":"1996","unstructured":"White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996;94(8):1826.","journal-title":"Circulation"},{"issue":"6","key":"345_CR3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCOUTCOMES.110.957878","volume":"3","author":"HL Nguyen","year":"2010","unstructured":"Nguyen HL, Gore JM, Saczynski JS, et al. Age and sex differences and 20-year trends (1986\u20132005) in prehospital delay in patients hospitalized with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2010;3(6):590\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"345_CR4","first-page":"1285","volume":"164","author":"JM Boucher","year":"2001","unstructured":"Boucher JM, Racine N, Thanh TH, et al. Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. CMAJ. 2001;164(9):1285.","journal-title":"CMAJ"},{"key":"345_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijcard.2015.04.227","volume":"192","author":"G Helft","year":"2015","unstructured":"Helft G, Georges JL, Mouranche X, et al. Outcomes of primary percutaneous coronary interventions in nonagenarians with acute myocardial infarction. Int J Cardiol. 2015;192:24\u20139.","journal-title":"Int J Cardiol"},{"issue":"8","key":"345_CR6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archinte.163.8.965","volume":"163","author":"U Stenestrand","year":"2003","unstructured":"Stenestrand U, Wallentin L. Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RISK-HIA). Fibrinolytic therapy in patients 75\u00a0years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med. 2003;163(8):965\u201371.","journal-title":"Arch Intern Med"},{"key":"345_CR7","doi-asserted-by":"crossref","unstructured":"Rosengren A, Wallentin L, Simoons M, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006;27(7):789\u201395.","DOI":"10.1093\/eurheartj\/ehi774"},{"issue":"4","key":"345_CR8","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362\u2013425.","journal-title":"Circulation"},{"issue":"20","key":"345_CR9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"issue":"2","key":"345_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jamainternmed.2014.6573","volume":"175","author":"AN Vora","year":"2015","unstructured":"Vora AN, Holmes DN, Rokos I, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. JAMA Intern Med. 2015;175(2):207\u201315.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"345_CR11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamainternmed.2014.6586","volume":"175","author":"MJ Claeys","year":"2015","unstructured":"Claeys MJ. Is primary percutaneous coronary intervention still the superior reperfusion strategy? JAMA Intern Med. 2015;175(2):216\u20137.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"345_CR12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archinternmed.2011.57","volume":"171","author":"MJ Claeys","year":"2011","unstructured":"Claeys MJ, de Meester A, Convens C, et al. Contemporary mortality differences between primary percutaneous coronary intervention and thrombolysis in ST-segment elevation myocardial infarction. Arch Intern Med. 2011;171(6):544\u20139.","journal-title":"Arch Intern Med"},{"issue":"7","key":"345_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.2010.1139","volume":"304","author":"CJ Terkelsen","year":"2010","unstructured":"Terkelsen CJ, Sorensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763\u201371.","journal-title":"JAMA"},{"issue":"15","key":"345_CR14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","volume":"368","author":"PW Armstrong","year":"2013","unstructured":"Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379\u201387.","journal-title":"N Engl J Med"},{"issue":"8478","key":"345_CR15","first-page":"397","volume":"1","author":"No authors listed","year":"1986","unstructured":"No authors listed. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell\u2019Infarto Miocardico (GISSI). Lancet. 1986;1(8478):397.","journal-title":"Lancet"},{"key":"345_CR16","unstructured":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349."},{"issue":"5","key":"345_CR17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0735-1097(91)90859-8","volume":"17","author":"S Sherry","year":"1991","unstructured":"Sherry S, Marder VJ. Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly. J Am Coll Cardiol. 1991;17(5):1237.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"345_CR18","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/01.CIR.101.19.2239","volume":"101","author":"DR Thiemann","year":"2000","unstructured":"Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000;101(19):2239.","journal-title":"Circulation"},{"issue":"9247","key":"345_CR19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/S0140-6736(00)03397-3","volume":"356","author":"HD White","year":"2000","unstructured":"White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028.","journal-title":"Lancet"},{"issue":"5","key":"345_CR20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archinte.162.5.561","volume":"162","author":"SB Soumerai","year":"2002","unstructured":"Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch Intern Med. 2002;162(5):561.","journal-title":"Arch Intern Med"},{"issue":"2","key":"345_CR21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0735-1097(00)00723-3","volume":"36","author":"AK Berger","year":"2000","unstructured":"Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy in older patients. J Am Coll Cardiol. 2000;36(2):366.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"345_CR22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa025142","volume":"349","author":"HR Andersen","year":"2003","unstructured":"Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733.","journal-title":"N Engl J Med."},{"issue":"8","key":"345_CR23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.amjcard.2009.05.054","volume":"104","author":"O Koeth","year":"2009","unstructured":"Koeth O, Zahn R, Gitt AK, et al. Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry). Am J Cardiol. 2009;104(8):1074\u20137.","journal-title":"Am J Cardiol"},{"issue":"8893","key":"345_CR24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","volume":"343","author":"No authors listed","year":"1994","unstructured":"No authors listed. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists\u2019 (FTT) Collaborative Group. Lancet. 1994;343(8893):311.","journal-title":"Lancet"},{"key":"345_CR25","unstructured":"Grines C. SENIOR PAMI: a prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. Presented at: Transcatheter Cardiovascular Therapeutics 2005; October 19, 2005; Washington, DC."},{"issue":"11","key":"345_CR26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0735-1097(02)01878-8","volume":"39","author":"MJ Boer de","year":"2002","unstructured":"de Boer MJ, Ottervanger JP, van\u2019t Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol. 2002;39(11):1723.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"345_CR27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/eurheartj\/ehq375","volume":"32","author":"H Bueno","year":"2011","unstructured":"Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32(1):51\u201360.","journal-title":"Eur Heart J"},{"issue":"1","key":"345_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2014.07.032","volume":"176","author":"E Binsell-Gerdin","year":"2014","unstructured":"Binsell-Gerdin E, Graipe A, Ogren J, Jernberg T, Mooe T. Hemorrhagic stroke the first 30 days after an acute myocardial infarction: incidence, time trends and predictors of risk. Int J Cardiol. 2014;176(1):133\u20138.","journal-title":"Int J Cardiol"},{"issue":"24","key":"345_CR29","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1053\/euhj.2001.2686","volume":"22","author":"FJ Werf Van de","year":"2001","unstructured":"Van de Werf FJ, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253.","journal-title":"Eur Heart J"},{"issue":"20","key":"345_CR30","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ehj.2003.07.004","volume":"24","author":"S Savonitto","year":"2003","unstructured":"Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb\/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J. 2003;24(20):1807\u201314.","journal-title":"Eur Heart J"},{"key":"345_CR31","doi-asserted-by":"crossref","unstructured":"Sinnaeve PR, Huang Y, Bogaerts K, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006;152(4):684 e1\u20139.","DOI":"10.1016\/j.ahj.2006.07.005"},{"issue":"9","key":"345_CR32","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/eurheartj\/ehm081","volume":"28","author":"HD White","year":"2007","unstructured":"White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, Antman EM. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J. 2007;28(9):1066\u201371.","journal-title":"Eur Heart J"},{"issue":"20","key":"345_CR33","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/01.wnl.0000435550.83200.9e","volume":"81","author":"H Gensicke","year":"2013","unstructured":"Gensicke H, Zinkstok SM, Roos YB, et al. IV thrombolysis and renal function. Neurology. 2013;81(20):1780\u20138.","journal-title":"Neurology"},{"issue":"8971","key":"345_CR34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0140-6736(95)92224-5","volume":"346","author":"No authors listed","year":"1995","unstructured":"No authors listed. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet. 1995;346(8971):329.","journal-title":"Lancet"},{"issue":"16","key":"345_CR35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199710163371603","volume":"337","author":"No authors listed","year":"1997","unstructured":"No authors listed. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med. 1997;337(16):1118.","journal-title":"N Engl J Med"},{"issue":"5","key":"345_CR36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0002-8703(99)70400-X","volume":"137","author":"FJ Werf Van de","year":"1999","unstructured":"Van de Werf FJ, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999;137(5):786.","journal-title":"Am Heart J"},{"issue":"2","key":"345_CR37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.95.2.351","volume":"95","author":"CP Cannon","year":"1997","unstructured":"Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95(2):351.","journal-title":"Circulation"},{"issue":"25","key":"345_CR38","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/01.CIR.98.25.2805","volume":"98","author":"CP Cannon","year":"1998","unstructured":"Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98(25):2805.","journal-title":"Circulation"},{"issue":"9","key":"345_CR39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0002-9149(99)00483-X","volume":"84","author":"CM Gibson","year":"1999","unstructured":"Gibson CM, Cannon CP, Murphy SA, et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol. 1999;84(9):976\u201380.","journal-title":"Am J Cardiol"},{"issue":"1","key":"345_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mhj.2001.112092","volume":"141","author":"F Wang-Clow","year":"2001","unstructured":"Wang-Clow F, Fox NL, Cannon CP, et al. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001;141(1):33.","journal-title":"Am Heart J"},{"key":"345_CR41","doi-asserted-by":"crossref","unstructured":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet. 1999;354(9180):716.","DOI":"10.1016\/S0140-6736(99)07403-6"},{"issue":"11","key":"345_CR42","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0002-9149(01)02084-7","volume":"88","author":"BG Angeja","year":"2001","unstructured":"Angeja BG, Alexander JH, Chin R, et al. Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am J Cardiol. 2001;88(11):1240.","journal-title":"Am J Cardiol"},{"key":"345_CR43","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358(9282):605.","DOI":"10.1016\/S0140-6736(01)05775-0"},{"issue":"21","key":"345_CR44","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","volume":"358","author":"SG Ellis","year":"2008","unstructured":"Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358(21):2205\u201317.","journal-title":"N Engl J Med"},{"issue":"17","key":"345_CR45","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.288.17.2130","volume":"288","author":"AM Lincoff","year":"2002","unstructured":"Lincoff AM, Califf RM, van de Werf FJ, et al. Mortality at 1 year with combination platelet glycoprotein IIb\/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288(17):2130.","journal-title":"JAMA"},{"issue":"14","key":"345_CR46","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCULATIONAHA.114.009570","volume":"130","author":"PR Sinnaeve","year":"2014","unstructured":"Sinnaeve PR, Armstrong PW, Gershlick AH, et al. STEMI patients randomized to a pharmaco-invasive strategy or primary PCI: the STREAM 1-year mortality follow-up. Circulation. 2014;130(14):1139\u201345.","journal-title":"Circulation"},{"issue":"8","key":"345_CR47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-129-8-199810150-00002","volume":"129","author":"JH Gurwitz","year":"1998","unstructured":"Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med. 1998;129(8):597.","journal-title":"Ann Intern Med"},{"key":"345_CR48","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Zheng Y, Westerhout CM, et al. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: insights from the strategic reperfusion early after myocardial infarction trial. Am Heart J 2015;169(6):890\u2013898 e1.","DOI":"10.1016\/j.ahj.2015.03.011"},{"issue":"10","key":"345_CR49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/eurheartj\/ehr403","volume":"33","author":"DM Larson","year":"2012","unstructured":"Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J. 2012;33(10):1232\u201340.","journal-title":"Eur Heart J"},{"issue":"15","key":"345_CR50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","volume":"370","author":"G Meyer","year":"2014","unstructured":"Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"345_CR51","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/ijs.12486","volume":"10","author":"Y Huang","year":"2015","unstructured":"Huang Y, Sharma VK, Robinson T, et al. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2\u00a0\u00d7\u00a02 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Int J Stroke. 2015;10(5):778\u201388.","journal-title":"Int J Stroke"},{"issue":"9497","key":"345_CR52","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607\u201321.","journal-title":"Lancet"},{"issue":"6","key":"345_CR53","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ahj.2003.12.028","volume":"147","author":"PR Sinnaeve","year":"2004","unstructured":"Sinnaeve PR, Alexander JH, Bogaerts K, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J. 2004;147(6):993.","journal-title":"Am Heart J"},{"issue":"2","key":"345_CR54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108(2):135.","journal-title":"Circulation"},{"issue":"14","key":"345_CR55","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477\u201388.","journal-title":"N Engl J Med"},{"key":"345_CR56","doi-asserted-by":"crossref","unstructured":"Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510):569\u201378.","DOI":"10.1016\/S0140-6736(06)68147-6"},{"issue":"9336","key":"345_CR57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(02)09963-4","volume":"360","author":"E Bonnefoy","year":"2002","unstructured":"Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360(9336):825.","journal-title":"Lancet"},{"issue":"9612","key":"345_CR58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(08)60268-8","volume":"371","author":"C Mario Di","year":"2008","unstructured":"Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371(9612):559\u201368.","journal-title":"Lancet"},{"issue":"12","key":"345_CR59","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179\u201389.","journal-title":"N Engl J Med"},{"issue":"9272","key":"345_CR60","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","volume":"357","author":"EJ Topol","year":"2001","unstructured":"Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357(9272):1905.","journal-title":"Lancet"},{"issue":"2","key":"345_CR61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacc.2009.08.007","volume":"55","author":"E Bohmer","year":"2010","unstructured":"Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55(2):102\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"345_CR62","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa0808276","volume":"360","author":"WJ Cantor","year":"2009","unstructured":"Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705\u201318.","journal-title":"N Engl J Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0345-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0345-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T04:58:41Z","timestamp":1567573121000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0345-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0345-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}